Cabolong 20 mg contains Cabozantinib, an oral multi-kinase inhibitor used in the treatment of certain advanced cancers.
By targeting multiple pathways that tumours rely on for growth and blood supply, Cabolong offers an effective option in cancers that are otherwise difficult to control.
Taken daily as a tablet, it allows patients to continue their cancer therapy at home under close medical supervision.

Mechanism of Action

Cabozantinib is a tyrosine kinase inhibitor (TKI) that acts on several key receptors involved in tumour growth and spread:

• VEGFR (vascular endothelial growth factor receptors) – inhibiting blood vessel formation (angiogenesis), starving tumours of nutrients and oxygen.

• MET and AXL receptors – which play roles in cancer cell survival, invasion, and metastasis.

• It also targets RET, which is important in certain thyroid cancers

  Uses / Indications

  Cabolong (cabozantinib) is indicated for the treatment of:

  • Advanced renal cell carcinoma (kidney cancer), either as first-line therapy or after progression on other treatments.

  • Hepatocellular carcinoma (liver cancer) in patients who have previously been treated with sorafenib.

  • Medullary thyroid carcinoma, especially when it cannot be removed by surgery or has spread.

    Adverse Effects

    Because cabozantinib targets pathways also used by healthy tissues (like blood vessels and the gastrointestinal lining), it can lead to several side effects.

    Common side effects include:

    • Diarrhoea, nausea, decreased appetite, weight loss.

    • Fatigue, taste changes.

    • Hand-foot syndrome (palmar-plantar erythrodysesthesia), causing redness, swelling, or pain in palms and soles.

    • Mild high blood pressure (hypertension).